NEW YORK (GenomeWeb) – Foundation Medicine is making efforts on several fronts to increase reimbursement for its cancer genomic profiling tests by public and private payors in the US and abroad, including submitting its FoundationOne test for parallel review by the US Food and Drug Administration and the Centers for Medicare and Medicaid Services and opening a laboratory in Germany to take advantage of that country's recently updated reimbursement codes.